Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Per Norlén
|
| gptkbp:country |
gptkb:Denmark
|
| gptkbp:focus |
infectious diseases
immunotherapy AI-driven immunotherapies |
| gptkbp:founded |
2008
|
| gptkbp:headquarters_location |
gptkb:Copenhagen
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evaxion Biotech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:pipeline |
EVX-01
EVX-02 EVX-B1 EVX-B2 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
EVAX
|
| gptkbp:technology |
AI-based drug discovery
|
| gptkbp:website |
https://www.evaxion-biotech.com/
|
| gptkbp:bfsParent |
gptkb:Novo_Holdings
|
| gptkbp:bfsLayer |
7
|